Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform - Slideshow (NASDAQ:ARCT) 2026-09-24
Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript
Arcturus Therapeutics Says ARCT-810 Generally Safe And Well Tolerated, Demonstrating Encouraging Activity Across Key Urea Cycle Biomarkers In Ongoing Phase 2 Study